Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medivir’s Lipsovir MAA wins validation from regulatory authorities
The authorities will start the review process to evaluate the data submitted by Medivir. The outcome of this review is expected to be received in the late part
The authorities will start the review process to evaluate the data submitted by Medivir. The outcome of this review is expected to be received in the late part
According to the company, the MGuard stent system presents a novel combination of a coronary stent merged with an embolic protection device. Lifelong embolic protection is achieved by
Wyeth is seeking an indication for the prevention of pneumococcal disease caused by the 13 serotypes included in the investigational vaccine in infants and children from two months
Through the special protocol assessment (SPA), the FDA has agreed that if the 131I-TM601 Phase III study successfully meets its stated endpoints, the design and planned analysis of
According to the company, both the PN 400-301/302 studies achieved the primary endpoints. Subjects taking PN 400 experienced statistically significantly fewer endoscopically confirmed gastric ulcers on PN 400
The current 10.6 month median overall survival advantage observed in the OGX-011 arm represents an increase over the median survival observed in the control arm. Docetaxel was approved
The US Patent and Trademark office has issued a patent for the exclusive use of a vaccine comprised of the two most prevalent surface antigens in Staphylococcus aureus
The Medtronic Sprint Quattro Secure S lead is designed with an 8.6 French diameter lead body. A thin wire inserted into the chambers of the heart through blood
As part of this filing, the company is seeking court approval of a sales procedures motion that will allow Introgen to market its therapeutic portfolio and other assets
The issued claims not only focus on siRNA but also include specific claims directed to micro RNA (miRNA), pre-miRNA, and short hairpin RNA (shRNA). This patent issues from